Recipharm publishes annual report 2015

Recipharm publishes today its annual report for 2015. The report is available on
the Company’s website. The printed version will be available later in April.
The annual report is also attached in this announcement.

For more information please visit www.recipharm.com or contact:
Björn Westberg, CFO, ir@recipharm.com, telephone: +46 8 602 46 20

This information is published in accordance with the Swedish Securities Market
Act, the Swedish Financial Instruments Trading Act and/or the regulations of
NASDAQ Stockholm. This information was submitted for publication on 5 April
2016, at 13:00 CET.

About Recipharm
Recipharm is a leading CDMO (Contract Development and Manufacturing
Organisation) in the pharmaceutical industry employing some 2,700 employees.
Recipharm offers manufacturing services of pharmaceuticals in various dosage
forms, production of clinical trial material including API and pharmaceutical
product development. Recipharm manufactures several hundred different products
to customers ranging from Big Pharma to smaller research- and development
companies. Recipharm’s turnover is approximately SEK 3.4 billion and the Company
operates development and manufacturing facilities in France, Germany, Italy,
Israel, Portugal, Spain, Sweden and the UK and is headquartered in Jordbro,
Sweden. The Recipharm B-share (RECI B) is listed on NASDAQ Stockholm.

For more information on Recipharm and our services, please visit
www.recipharm.com
Recipharm AB (publ)
Corporate identity number 556498-8425
Address Lagervägen 7, SE-136 50 Jordbro, Sweden, Telephone 46 8 602 52
00, Fax 46 8 81 87 03
www.recipharm.com